<DOC>
	<DOC>NCT01502137</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.</brief_summary>
	<brief_title>Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>PATIENTS: Male or female, age equal to or above 18 years undergoing chronic haemodialysis Stable and adequate haemodialysis treatment three months prior to enrolment HEALTHY SUBJECTS: Matching an individual of the patient group by: Gender and age (± 5 years) Matching an individual of the patient group by weight (after dialysis, ±10%) Creatinine clearance above 80 ml/min Subjects must be in good health in accordance with their age as determined by a medical history, physical examination, vital signs, ECG (electrocardiogram), routine haematology and clinical chemistry Use of cuprophane membranes Active malignant disease Diabetes Critical illness as defined by the need of respiratory or circulatory support Known or suspected allergy to the trial product Pregnancy, breast feeding, the intention of becoming pregnant or fertile women judged to be using inadequate contraceptive measures Blood Pressure (predialysis) above 180/110 Chronic treatment with steroids in doses above 10 mg/day prednisolone (or equivalent) Treated with immunosuppressive agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>